Effect of pioglitazone on survival and renal function in a mouse model of polycystic kidney disease

American Journal of Nephrology

Volumn 30, Issue 5, 2009, Pages 468-473

  Raphael, K L ^a   Strait, K A ^a   Stricklett, P K ^a   Baird, B C ^a   Piontek, K ^b   Germino, G G ^b   Kohan, D E ^a  

^a UNIVERSITY OF UTAH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blood pressure; Pioglitazone; Polycystic kidney disease

Indexed keywords

PIOGLITAZONE; POLYCYSTIN 1; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; APOPTOSIS; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE MUTATION; KIDNEY FUNCTION; KIDNEY MASS; KIDNEY POLYCYSTIC DISEASE; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; UREA BLOOD LEVEL;

ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; HYPERTENSION, RENAL; HYPOGLYCEMIC AGENTS; KAPLAN-MEIERS ESTIMATE; KIDNEY; MICE; MICE, KNOCKOUT; POLYCYSTIC KIDNEY DISEASES; THIAZOLIDINEDIONES; TRPP CATION CHANNELS;

EID: 70349258273     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000242432     Document Type: Article

References (17)

1. Sarafidis PA, Bakris GL: Protection of the kidney by thiazolidinediones: An assessment from bench to bedside. Kidney Int 2006; 70: 1223-1233.
2. Szeto CC, Li PK: Antiproteinuric and antiinflammatory effects of thiazolidinedione. Nephrology (Carlton) 2008; 13: 53-57.
3. Blanquicett C, Roman J, Hart CM: Thiazolidinediones as anti-cancer agents. Cancer Ther 2008; 6: 25-34.
4. Simons M, Walz G: Polycystic kidney disease: Cell division without a c(l)ue? Kidney Int 2006; 70: 854-864.
5. Raphael KL, Strait KA, Stricklett PK, Miller RL, Nelson RD, Piontek KB, Germino GG, Kohan DE: Inactivation of Pkd1 in principal cells causes a more severe cystic kidney disease than in intercalated cells. Kidney Int 2009 ; 75: 626-633.
6. Rodriguez WE, Tyagi N, Joshua IG, Passmore JC, Fleming JT, Falcone JC, Tyagi SC: Pioglitazone mitigates renal glomerular vascular changes in high-fat, high-calorie-induced type 2 diabetes mellitus. Am J Physiol Renal Physiol 2006; 291:F694-F701.
7. Ko GJ, Kang YS, Han SY, Lee MH, Song HK, Han KH, Kim HK, Han JY, Cha DR: Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol Dial Transplant 2008 ; 23: 2750-2760.
8. Namikoshi T, Satoh M, Tomita N, Haruna Y, Kobayashi S, Komai N, Sasaki T, Kashihara N: Pioglitazone ameliorates endothelial dysfunction in obese rats with nephropathy. Biochem Biophys Res Commun 2007; 361: 835-840.
9. Omasu F, Oda T, Yamada M, Yoshizawa N, Yamakami K, Sakurai Y, Miura S: Effects of pioglitazone and candesartan on renal fibrosis and the intrarenal plasmin cascade in spontaneously hypercholesterolemic rats. Am J Physiol Renal Physiol 2007; 293:F1292-1298.
10. Muto S, Aiba A, Saito Y, Nakao K, Nakamura K, Tomita K, Kitamura T, Kurabayashi M, Nagai R, Higashihara E, Harris PC, Katsuki M, Horie S: Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet 2002; 11: 1731-1742.
11. Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Bae KT, Baumgarten DA, Kenney PJ, King BF, Jr., Glockner JF, Wetzel LH, Brummer ME, O'Neill WC, Robbin ML, Bennett WM, Klahr S, Hirschman GH, Kimmel PL, Thompson PA, Miller JP: Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The consortium for radiologic imaging studies of polycystic kidney disease (CRISP) cohort. Kidney Int 2003; 64: 1035-1045.
12. Hamblin M, Chang L, Zhang J, Chen YE: The role of peroxisome proliferator-activated receptor gamma in blood pressure regulation. Curr Hypertens Rep 2009; 11: 239-245.
13. Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD: Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005; 11: 861-866.
14. Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T: Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione- induced fluid retention. Proc Natl Acad Sci USA 2005; 102: 9406-9411.
15. Yoder BK, Mulroy S, Eustace H, Boucher C, Sandford R: Molecular pathogenesis of autosomal dominant polycystic kidney disease. Expert Rev Mol Med 2006; 8: 1-22.
16. Makino H, Miyamoto Y, Sawai K, Mori K, Mukoyama M, Nakao K, Yoshimasa Y, Suga S: Altered gene expression related to glomerulogenesis and podocyte structure in early diabetic nephropathy of db/db mice and its restoration by pioglitazone. Diabetes 2006; 55 : 2747-2756.
17. Ohtomo S, Izuhara Y, Takizawa S, Yamada N, Kakuta T, van Ypersele de Strihou C, Miyata T: Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model. Kidney Int 2007; 72: 1512-1519.